Oxygen-Enhanced MRI for Brain Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method of using MRI scans to map oxygen levels in brain tumors. Tumors often have low oxygen, reducing the effectiveness of treatments like radiation and chemotherapy. Oxygen-enhanced MRI (Magnetic Resonance Imaging) aims to provide a clearer picture of tumor oxygen levels, allowing for more tailored treatments. The trial seeks adults with known or suspected brain tumors who are planning to undergo or have already received treatment. As an unphased trial, it offers patients a unique opportunity to contribute to innovative research that could enhance future treatment strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that oxygen-enhanced MRI is safe for brain tumor patients?
Research has shown that oxygen-enhanced MRI, which involves breathing extra oxygen during the scan, is generally safe. Studies have found this method to be non-invasive and well-tolerated by patients. For instance, one study found it worked well for head and neck cancer patients without causing significant side effects. Another study noted that while researchers often use this technique in animal research, it is considered safe for humans too. Overall, evidence suggests no major safety concerns with oxygen-enhanced MRI, making it a promising option for understanding and treating brain tumors.12345
Why are researchers excited about this trial?
Researchers are excited about oxygen-enhanced MRI for brain tumors because it offers a new way to visualize tumor oxygenation levels in real-time. Unlike standard MRI, which provides structural images, this technique involves patients breathing supplemental oxygen during the scan, potentially highlighting areas of the tumor that are more or less oxygenated. This could help tailor treatments more precisely, as tumor oxygenation is known to affect how well tumors respond to therapies like radiation. By enhancing the MRI with oxygen, doctors might better understand the tumor's environment, potentially leading to more effective treatment plans.
What evidence suggests that oxygen-enhanced MRI is effective for generating hypoxia maps in brain tumors?
Research has shown that oxygen-enhanced MRI (OE-MRI), which participants in this trial will undergo, can effectively detect low oxygen levels in brain tumors. During the trial, patients receive supplemental oxygen while undergoing standard MRI, resulting in clearer images of the tumor. This method measures low oxygen levels without surgery or other invasive procedures. Understanding oxygen levels in tumors is crucial because low levels can reduce the effectiveness of radiation and chemotherapy. By gaining insights into tumor oxygenation, doctors can adjust treatments to improve outcomes for each patient.13678
Who Is on the Research Team?
Ramon Barajas
Principal Investigator
OHSU Knight Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a suspected or known brain tumor larger than 10 mL. Participants must be able to consent, have a performance score indicating they can carry out daily activities, and may already be receiving treatment for the tumor. It's not suitable for those with sickle cell disease, poor vein access, pregnancy, certain metal implants, severe other illnesses or conditions that make MRI or oxygen therapy risky.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Imaging
Patients receive supplemental oxygen while undergoing standard of care MRI to generate hypoxia maps
Follow-up
Participants are monitored for progression free survival and other outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Magnetic Resonance Imaging
- Oxygen Therapy
Magnetic Resonance Imaging is already approved in United States for the following indications:
- Non-small cell lung cancer with KRAS G12C mutation
- Advanced colorectal cancer that is wild-type RAS
Find a Clinic Near You
Who Is Running the Clinical Trial?
OHSU Knight Cancer Institute
Lead Sponsor
Oregon Health and Science University
Collaborator